Financing ·
Genmab raises DKK 370M via employee warrant exercise, increasing share capital by 164,828 shares
GMABGenmab A/S
Genmab A/S increased its share capital by 164,828 shares following the exercise of employee warrants. The company raised approximately DKK 369.7 million in proceeds from the cash subscription. The transaction was executed without preemption rights for existing shareholders and represents a dilution of approximately 0.2641% to the total share capital. The new ordinary shares are freely transferable and carry full dividend rights from the date of subscription. Genmab is an international biotechnology company focused on developing innovative antibody medicines, including bispecific antibodies and antibody-drug conjugates, for cancer and other serious diseases.